Copay help by condition · Cancer and blood cancer · read 2026-11-08
Mantle Cell Lymphoma (MCL): which charitable copay funds are open
2 funds for Mantle Cell Lymphoma say it is open right now, of the 2 we hold (read 2026-11-08).
Open: Mantle Cell Lymphoma from HealthWell Foundation and Mantle cell lymphoma (MCL) from TotalAssist (Patient Advocate Foundation copay funds). Eligibility is each fund's own rule.
If you have Medicare Part D: CMS prints the annual out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026) (Table V-2 of its CY 2027 announcement). It is a benefit parameter and applies to covered drugs under plan rules. What changes on January 1.
Swipe to read across
A copy for a patient, a clinic or a pharmacist, with each source and the date we read it.
Every fund we hold for Mantle Cell Lymphoma
- OpenMantle Cell Lymphoma
HealthWell Foundation ·
Award level: not statedInsurance supported: not stated
The page lists the fund as Open. Source page
- OpenMantle cell lymphoma (MCL)
TotalAssist (Patient Advocate Foundation copay funds) ·
Award level: $5,000Insurance supported: Medicaid, Medicare, TRICARE
The page lists the fund as Open. Source page
Drugs whose FDA label names Mantle Cell Lymphoma
4 drugs. Each row quotes the sentence of the drug's FDA label (Indications and Usage, openFDA) that names the condition. A label naming a condition is not a statement that the drug is approved, effective or covered for you. Dashes in quotes are shown as hyphens. Of these, 3 have a program (in our assistance finder or on the program's own page) and 1 has a Medicare negotiated price in the CMS file; an empty cell says we found nothing in our data, not that nothing exists.
| Drug | What the FDA label says | Manufacturer program | Medicare negotiated price |
|---|---|---|---|
| Calquence Acalabrutinib Every route for this drug | In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT). Label on openFDA, read 2026-11-10 | AZ&Me Prescription Savings Program Limited | $8,600.00 for a 30-day supply, effective 2027-01-01 |
| Revlimid Lenalidomide Every route for this drug | Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1. Label on openFDA, read 2026-11-10 | BMS Access Support Cancer Drug Assistance (Multiple Programs) Bristol Myers Squibb Patient Assistance Foundation (program page) additional REMS requirements | not in the CMS negotiated-price file |
| Jaypirca Pirtobrutinib Every route for this drug | Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. Label on openFDA, read 2026-11-10 | Lilly Cares Foundation Patient Assistance Program | not in the CMS negotiated-price file |
| Brukinsa Zanubrutinib | Mantle cell lymphoma (MCL) who have received at least one prior therapy. Label on openFDA, read 2026-11-10 | not in our assistance finder | not in the CMS negotiated-price file |
Funds for costs around Mantle Cell Lymphoma
These pay for a kind of cost, not a diagnosis. Each is shown with its own status.
Funds for costs around cancer and blood cancer in general: behavioral health (1 open of 2), caregiver support (0 open of 2), clinical trial costs (0 open of 1), home care (1 open of 1), named fund (0 open of 1), pain management (0 open of 1), testing (1 open of 1) and transportation (0 open of 1). Every one is listed, with its source, on the Cancer and blood cancer page.
Related conditions
No broader or more specific condition page for this one.
Group: Cancer and blood cancer. All conditions: the condition index. Fund board for every condition: charitable copay fund status.
What changed
First read on 2026-11-08. We keep each read with its date, so a fund reopening or closing will show here as a change. Until we have a second read there is nothing to compare, and we do not guess. The read date of every source is on the changes page.
This page as data
The same facts as JSON, each fund with its source URL and read date: mantle-cell-lymphoma.json. Edition 2026-11, root 006ab9a329709cbe. See the licence page.
Questions
Is there an open charitable copay fund for Mantle Cell Lymphoma?
As read on 2026-11-08, 2 of the 2 funds we hold for Mantle Cell Lymphoma say they are open: Mantle Cell Lymphoma from HealthWell Foundation and Mantle cell lymphoma (MCL) from TotalAssist (Patient Advocate Foundation copay funds). Funds open and close, so check the source page before you apply.
Which organizations run funds for Mantle Cell Lymphoma?
HealthWell Foundation and TotalAssist (Patient Advocate Foundation copay funds). Each fund row on this page links to the organization's own page.
Does an open fund mean I qualify?
No. A status says whether a fund is taking applications. Eligibility, award level and which insurance it supports are each fund's own rules; where the page states them they are shown on the fund.
How current is this page?
Statuses are what each fund's own page said on the date we read it (2026-11-08). We do not promise a fund is still in that state today.